Bioncotech was founded in the year 2010 following the findings of the research group of Dr. Marisol Soengas. The main objective of the company is to develop therapies against validated cancer targets, with BO-112 having entered clinical stage in the year 2017. The initial clinical results were presented in the 2018 Congress 2018 of the European Society of Medical Oncology.
Bioncotech is a VC-funded, clinical-stage, immune-oncology company with offices in Madrid and Valencia in Spain. It develops cutting-edge RNA-based therapies against validated and novel targets in cancer and immune cells. The team of seasoned drug developers, supported by world-renowned scientific and clinical advisors, is dedicated to bring developed therapies to patients in need.
The company’s lead drug, BO-112, induces immunogenic cell death in solid tumors and simultaneously activates the innate immune system to ensure optimal antigen processing and presentation to the adaptive immune system. BO-112 initiates a powerful immune reaction (turning ‘cold’ tumors ‘hot’), that is highly synergistic with checkpoint inhibitors to achieve deep and sustained anti-tumor responses. The drug has yet proven its safety and successful development of the expected biological effect in monotherapy assays. BO-112 is currently being researched in clinical trials as a monotherapy and in combination with checkpoint inhibitors.